Press coverage about Fulgent Genetic (NASDAQ:FLGT) has been trending positive on Tuesday, Accern reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Fulgent Genetic earned a media sentiment score of 0.29 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.5635813040163 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of Fulgent Genetic (NASDAQ:FLGT) traded down 6.86% during trading on Tuesday, reaching $3.94. 9,601 shares of the company were exchanged. The company’s 50-day moving average is $4.47 and its 200 day moving average is $4.51. The firm’s market capitalization is $69.90 million. Fulgent Genetic has a 1-year low of $3.60 and a 1-year high of $13.90.
Fulgent Genetic (NASDAQ:FLGT) last announced its earnings results on Monday, August 7th. The company reported $0.02 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.02. The company had revenue of $4.64 million during the quarter, compared to the consensus estimate of $5.03 million. Fulgent Genetic had a negative net margin of 0.42% and a negative return on equity of 0.02%. Equities research analysts expect that Fulgent Genetic will post $0.14 EPS for the current fiscal year.
A number of brokerages recently weighed in on FLGT. Zacks Investment Research upgraded shares of Fulgent Genetic from a “sell” rating to a “hold” rating in a report on Monday, July 10th. Piper Jaffray Companies restated an “overweight” rating and issued a $7.00 price objective (down from $10.00) on shares of Fulgent Genetic in a report on Wednesday, August 9th. ValuEngine upgraded shares of Fulgent Genetic from a “sell” rating to a “hold” rating in a report on Monday, October 2nd. Finally, Credit Suisse Group decreased their price objective on shares of Fulgent Genetic from $11.00 to $10.00 and set an “outperform” rating for the company in a report on Tuesday, August 8th.
ILLEGAL ACTIVITY NOTICE: This piece was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.com-unik.info/2017/10/31/fulgent-genetic-flgt-receiving-positive-news-coverage-analysis-finds.html.
In other Fulgent Genetic news, CFO Paul Kim sold 6,134 shares of the firm’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $5.71, for a total value of $35,025.14. Following the completion of the transaction, the chief financial officer now owns 388,602 shares of the company’s stock, valued at $2,218,917.42. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 58.80% of the company’s stock.
About Fulgent Genetic
Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.
What are top analysts saying about Fulgent Genetic? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fulgent Genetic and related companies.